Revenue

9 Months Ended

Jun. 30, 2023

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended June 30,				Nine Months Ended June 30,
(In thousands)	2023		2022		2023		2022
Medical Device
Product sales	$	9,299	$	6,741	$	25,593	$	19,970
Royalties		8,220		7,771		23,702		23,015
License fees		25,933		1,024		28,645		3,723
Research, development and other		2,562		1,992		6,799		6,181
Medical Device Revenue		46,014		17,528		84,739		52,889
In Vitro Diagnostics
Product sales		6,368		7,178		19,658		20,257
Research, development and other		101		148		217		817
In Vitro Diagnostics Revenue		6,469		7,326		19,875		21,074
Total Revenue	$	52,483	$	24,854	$	104,614	$	73,963

Contract assets totaled $7.7 million and $7.1 million as of June 30, 2023 and September 30, 2022, respectively, on the condensed consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangement.